Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGLE

AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

27.60USD-0.08 (-0.29%)Market Closed
Watchlist

Market Summary

USD27.60-0.08
Market Closed
-0.29%

AGLE Stock Price

View Fullscreen

AGLE RSI Chart

AGLE Valuation

Market Cap

111.8M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

106.03

EV/EBITDA

-0.07

Price/Free Cashflow

-1.28

AGLE Price/Sales (Trailing)

AGLE Profitability

EBT Margin

-27932.35%

Return on Equity

-64.57%

Return on Assets

-142.06%

Free Cashflow Yield

-77.9%

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

1.1M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

AGLE Earnings

Earnings (TTM)

-294.4M

Earnings Growth (Yr)

-119.96%

Earnings Growth (Qtr)

81.52%

Breaking Down AGLE Revenue

Last 7 days

14.0%

Last 30 days

51.4%

Last 90 days

158.0%

Trailing 12 Months

122.8%

How does AGLE drawdown profile look like?

AGLE Financial Health

Current Ratio

4.59

AGLE Investor Care

Shares Dilution (1Y)

64.56%

Diluted EPS (TTM)

-75.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.2M1.2M1.1M0
202220.1M7.0M5.8M2.3M
202100018.7M
20200000
20190000
20185.7M6.6M5.4M3.9M
20174.8M4.9M5.0M5.2M
20166.9M4.9M5.0M4.6M
20150006.1M

Tracking the Latest Insider Buys and Sells of Aeglea BioTherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 24, 2023
fairmount funds management llc
acquired
-
-
3,435,480
-
Nov 24, 2023
turtle cameron
acquired
-
-
723,440
chief executive officer
Aug 25, 2022
souza marcio
bought
50,472
0.5608
90,000
-
Jun 08, 2022
hanley jr. michael conick
bought
20,022
0.71
28,200
chief commercial officer
Mar 16, 2022
quinn anthony g.
bought
187,705
2.344
80,079
president & ceo
Mar 15, 2022
quinn anthony g.
bought
78,942
1.8611
42,417
president & ceo
Mar 14, 2022
quinn anthony g.
bought
130,221
1.93
67,472
president & ceo
Mar 11, 2022
quinn anthony g.
bought
71,779
2.064
34,777
president & ceo
Mar 11, 2022
alspaugh jonathan
bought
156,000
2.08
75,000
chief financial officer
Dec 13, 2021
shanafelt armen
bought
53,600
3.65
14,685
-

1–10 of 39

Which funds bought or sold AGLE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Virtus ETF Advisers LLC
new
-
134,263
134,263
0.09%
Feb 15, 2024
BARCLAYS PLC
new
-
979,000
979,000
-%
Feb 14, 2024
BVF INC/IL
new
-
14,786,000
14,786,000
0.37%
Feb 14, 2024
Blackstone Inc.
new
-
430,206
430,206
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
494
11,221,900
12,410,800
-%
Feb 14, 2024
Royal Bank of Canada
sold off
-100
-5,000
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
19.26
443,685
848,878
-%
Feb 14, 2024
SUVRETTA CAPITAL MANAGEMENT, LLC
unchanged
-
1,505,400
3,494,740
0.16%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
new
-
21,520,000
21,520,000
0.04%

1–10 of 47

Are Funds Buying or Selling AGLE?

Are funds buying AGLE calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGLE
No. of Funds

Unveiling Aeglea BioTherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
commodore capital lp
5.4%
1,934,084
SC 13G/A
Feb 14, 2024
perceptive advisors llc
7.2%
2,606,679
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
0.0%
0
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
0%
0
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.2%
2,232,760
SC 13G
Feb 14, 2024
ecor1 capital, llc
2.5%
887,076
SC 13G/A
Feb 14, 2024
rock springs capital management lp
0%
0
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
5.9%
2,125,597
SC 13G
Feb 14, 2024
logos global management lp
0.4%
150,000
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
9.99%
3,734,514
SC 13G/A

Recent SEC filings of Aeglea BioTherapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 20, 2024
4
Insider Trading
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Aeglea BioTherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
5.8B
107.9M
-3.85% 226.12%
-9.38
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aeglea BioTherapeutics Inc News

Latest updates
PR Newswire3 months ago
Quartz3 months ago

Aeglea BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-100.0%-688,000198,000168,000174,000625,0001,362,0003,644,0001,399,00013,696,0009,160,0004,624,00088,000161,000300,000442,500585,000619,000309,500-6,000
Operating Expenses-88.5%18,337,000159,934,00019,004,00019,330,00018,929,00023,048,00025,803,00024,086,00021,692,00020,401,00018,209,00022,776,00018,123,00021,560,00019,022,00021,909,00022,146,00018,622,00017,657,00015,305,00012,243,000
  S&GA Expenses-28.8%8,584,00012,062,0005,228,0005,079,0006,952,0007,675,0008,825,0007,304,0006,839,0006,822,0006,354,0007,020,0005,672,0004,691,0004,460,0004,343,0004,307,0003,816,0003,268,0003,507,0003,314,000
  R&D Expenses---13,776,00014,251,00011,977,00015,373,00016,978,00016,782,00014,853,00013,579,00011,855,00015,756,00012,451,00016,869,00014,562,00017,566,00017,839,00014,806,00014,389,00011,798,0008,929,000
EBITDA Margin-26.0%-278-220-65.61-35.38-14.47-12.21-3.50-3.42-20.38-20.42-20.47-20.52---------
Income Taxes-57.1%3,0007,000-36,00051,000-209,0009,000-23,00026,00092,000-----------
Earnings Before Taxes81.5%-40,104,000-217,074,000-18,458,000-18,771,000-18,443,000-22,314,000-24,436,000-20,423,000-20,281,000-6,738,000--22,714,000-18,033,000-21,418,000-------
EBT Margin-25.8%-279-222-66.94-36.05-14.75-12.44-3.58-3.50-20.77-20.77-20.77-20.77---------
Net Income81.5%-40,107,000-217,081,000-18,422,000-18,822,000-18,234,000-22,323,000-24,436,000-20,446,000-20,307,000-6,830,000-18,218,000-22,714,000-18,033,000-21,418,000-18,728,000-21,495,000-21,573,000-18,019,000-17,167,000-14,898,000-11,917,000
Net Income Margin-25.9%-279-221-66.78-35.99-14.72-12.45-3.58-3.51-17.48-16.90-20.64-20.77---------
Free Cashflow-107.9%-34,597,000-16,643,000-17,634,000-18,140,000-15,069,000-20,673,000-26,300,000-19,268,000-17,093,0002,052,000-19,980,000-18,132,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-14.9%20724452.0071.0092.0010783.0011012914716416215617365.0083.0010011712978.0071.00
  Current Assets-14.1%20624044.0062.0082.0097.0073.0099.0011813415115014416254.0075.0093.0011012777.0070.00
    Cash Equivalents2919.7%91.003.0035.0035.0041.0037.0015.0015.0025.0035.0080.0090.0054.0066.0013.0019.0025.0025.0086.0022.0015.00
  Net PPE---3.003.004.004.004.005.005.005.006.006.005.005.004.002.001.001.001.001.001.00
Liabilities-74.1%66.0025419.0021.0024.0023.0022.0026.0027.0028.0040.0022.0019.0021.0022.0023.0020.0018.0012.0010.008.00
  Current Liabilities-80.7%45.0023213.0015.0018.0016.0016.0020.0020.0021.0032.0016.0014.0016.0017.0018.0015.0013.0012.0010.008.00
Shareholder's Equity0.5%45645434.0050.0068.0084.0062.0084.0010211912414013615243.0060.0080.0010011667.0064.00
  Retained Earnings-6.1%-701-661-444-425-406-388-366-341-321-301-294-276-253-235-213-195-173-152-134-116-101
  Additional Paid-In Capital0.5%456454478476475473428426423420418416390387257255253252250184166
Shares Outstanding25.0%4.003.003.003.004.003.003.002.003.003.003.002.00---------
Float------30.00---337---386---178---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-107.9%-34,597-16,643-17,634-18,140-15,068-20,673-26,263-19,268-17,0002,082-19,530-17,132-17,536-19,413-21,694-16,294-17,208-16,383-15,807-7,200-8,502
  Share Based Compensation150.4%4,7851,9111,7091,4271,5662,0172,1012,0942,1072,0801,7571,6121,6961,6001,3481,1841,3661,2451,0811,3771,072
Cashflow From Investing-1544.2%-97,6316,76017,75014,00016,49975025,7599,6635,777-47,3599,30028,6205,784-56,76114,75310,32616,012-42,01313,936-2,1321,399
Cashflow From Financing-106.0%-12,531209,99210.00-8.00-13042,80412.0080.001,143-19236224,679258129,293282676311-31965,05517,2611,056

AGLE Income Statement

2023-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 0$ 174$ 886$ 2,161
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Development Fee and Royalty [Member]Development Fee and Royalty [Member]Development Fee and Royalty [Member]Development Fee and Royalty [Member]
Operating expenses (income):    
Research and development[1]$ 24,660$ 11,977$ 55,822$ 44,328
General and administrative8,5846,95225,87423,452
Acquired in-process research and development(298)0130,1880
Gain recognized within operating expenses(14,609)0(14,609)0
Total operating expenses18,33718,929197,27567,780
Loss from operations(18,337)(18,755)(196,389)(65,619)
Other (expense) income:    
Interest income1,2512882,021427
Other income, net2,342242,26225
Total other (expense) income(21,767)312(79,247)452
Loss before income tax expense(40,104)(18,443)(275,636)(65,167)
Income tax (expense) benefit(3)20926174
Net loss$ (40,107)$ (18,234)$ (275,610)$ (64,993)
Net loss per share, basic (in dollars per share)$ (9.34)$ (4.84)$ (69.57)$ (20.17)
Net loss per share, diluted (in dollars per share)$ (9.34)$ (4.84)$ (69.57)$ (20.17)
Weighted-average common shares outstanding, basic (in dollars per share)4,293,8123,767,9183,961,5463,222,987
Weighted-average common shares outstanding, diluted (in dollars per share)4,293,8123,767,9183,961,5463,222,987
Forward contract liability    
Other (expense) income:    
Change in fair value of forward contract liability$ (25,360)$ 0$ (83,530)$ 0
[1]Includes $19.4 million and $20.8 million in related party expenses for the three and nine months ended September 30, 2023, respectively and no related party expenses for the three and nine months ended September 30, 2022.

AGLE Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS  
Cash and cash equivalents$ 90,592$ 34,863
Marketable securities113,00720,848
Development receivables163375
Prepaid expenses and other current assets2,1876,172
Total current assets205,94962,258
Restricted cash1,3071,553
Property and equipment, net03,220
Operating lease right-of-use assets03,430
Other non-current assets9683
TOTAL ASSETS207,26571,144
CURRENT LIABILITIES  
Accounts payable1,678677
CVR liability7,5100
Operating lease liabilities0625
Deferred revenue0517
Accrued and other current liabilities15,86112,837
Related party accounts payable19,8230
Total current liabilities44,87214,656
Non-current CVR liability20,6900
Non-current operating lease liabilities04,004
Deferred revenue, net of current portion02,179
TOTAL LIABILITIES65,56220,839
Commitments and Contingencies (Note 11)
STOCKHOLDERS’ (DEFICIT) EQUITY  
Preferred stock, $0.0001 par value; 8,913,659 shares and 10,000,000 authorized as of September 30, 2023 and December 31, 2022; no shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 20,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 4,048,687 shares and 2,614,014 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively76
Additional paid-in capital455,957475,971
Accumulated other comprehensive income (loss)(132)(48)
Accumulated deficit(701,234)(425,624)
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY(245,402)50,305
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY207,26571,144
Series A Non Voting Convertible Preferred Stock  
CURRENT LIABILITIES  
Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 and no shares authorized as of September 30, 2023 and December 31, 2022, respectively; 1,086,339 and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively$ 387,105$ 0
AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
 WEBSITEwww.aeglea.com
 EMPLOYEES14

Aeglea BioTherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Tue Jan 30 2024, market cap of Aeglea BioTherapeutics Inc is 111.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers. The fair value of Aeglea BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aeglea BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGLE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jan 30 2024, AGLE's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 106.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.